Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma - Delforge, M; Terpos, E; Richardson, P G (Eur J Haematol, 2011)
et al.